Netherton Syndrome Study with Quoin

Quoin Pharmaceuticals, Ltd. is developing a topical medication containing a new investigational active ingredient, combined with a proprietary polymer delivery system, for the treatment of Netherton syndrome. 

Quoin is now initiating two different studies under the guidance of FDA. 

1. Phase 2 Trial - must wash out any systemic medications (ie oral, injectable, etc.). Patients must be adults 18 years or older (not pregnant or breastfeeding females) in good general health with a clinical diagnosis of NS (genetic testing may also be required). Patients must have NS lesions on arms or lower legs, and be off NS medications in these areas.  Qualified patients will receive up to 12 weeks of treatment with the majority of patients (~66.6% of those enrolled) will receive active medication.
2. Open-label Trial - can stay on systemic medications (ie oral, injectable, etc.). Patients must be adults 18 years or older (not pregnant or breastfeeding females) in good general health with a clinical diagnosis of NS (genetic testing may also be required). Patients must have NS lesions on arms or lower legs. Patients will be able to continue their standard of care, including systemic therapy, for the duration of the study, but must be willing to wash out of their topical therapy, if any, in the area where the investigational treatment will be applied (i.e. arms or legs). Qualified patients will receive up to 12 weeks of treatment with all subjects receiving the active medication.

How to Participate

If you would like to be considered for either of these exciting studies, please complete a brief survey here to see if you may pre-qualify. Based upon the information provided in the survey, if you pre-qualify one of our Team Members will be contacting you to discuss potential next steps.

Details and survey can found here: https://www.nethertonsyndromeclinicaltrials.com/

Return to Clinical Trial Page